Mast Makes Board Appointment
This article was originally published in Scrip
San Diego-based Mast Therapeutics, a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure and stroke has named Peter Greenleaf to its board of directors. Greenleaf currently serves as CEO and a member of the board of Sucampo Pharmaceuticals Inc., which is focused on the development and commercialisation of medicines to meet major unmet medical needs worldwide. He currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Greenleaf is also a member of the board of the Biotechnology Industry Organization (BIO).
Register for our free email digests: